« Return to News | Clinical Intelligence

Omeros publishes research on MASP-2 data

Wednesday, April 20, 2011 12:11 PM

Omeros has published research on mannan-binding lectin-associated serine protease-2 (MASP-2) in the April 18, 2011 early online edition of the Proceedings of the National Academy of Sciences (PNAS). Wilhelm Schwaeble, Ph.D., professor of immunology at the University of Leicester and the senior author of the paper, led an international team of researchers who demonstrated that blocking MASP-2 function significantly reduces tissue damage caused by ischemia-reperfusion injury.

Schwaeble and his colleagues demonstrated in animal models of cardiac and gastrointestinal ischemia-reperfusion injury that inhibition of MASP-2 function blocked the excessive inflammatory response, resulting in significantly less tissue damage.

MASP-2 is a key component of the innate immune response and its inhibition could potentially provide a novel approach to treating other inflammatory disorders, including neuropathy and other complications of diabetes, age-related macular degeneration and autoimmune disorders.  Omeros holds worldwide exclusive intellectual-property rights related to MASP-2, the antibodies targeting MASP-2 and the therapeutic applications for those antibodies from the University of Leicester, from its collaborator, Medical Research Council at Oxford University, and from Helion Biotech ApS.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.